Cargando…

Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients

PURPOSE: Disseminated tumor cells (DTCs) from bone marrow (BM) are a surrogate of minimal residual disease (MRD) in primary breast cancer (PBC) patients and associated with an adverse prognosis. However, BM sampling is an invasive procedure. Although there is growing evidence that circulating tumor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hartkopf, Andreas D., Wallwiener, Markus, Hahn, Markus, Fehm, Tanja N., Brucker, Sara Y., Taran, Florin-Andrei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Cancer Association 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4720101/ https://www.ncbi.nlm.nih.gov/pubmed/25687853 http://dx.doi.org/10.4143/crt.2014.287

Ejemplares similares

The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy
por: Hartkopf, Andreas Daniel, et al.
Publicado: (2013)

Association between 21-gene-assay and detection of disseminated tumor cells in patients with early breast cancer: results from the IRMA trial
por: Volmer, Léa L., et al.
Publicado: (2023)

Prognostic relevance of induced and spontaneous apoptosis of disseminated tumor cells in primary breast cancer patients
por: Krawczyk, Natalia, et al.
Publicado: (2014)

Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany
por: Walter, Vincent P., et al.
Publicado: (2020)

The Brustkrebs-Studien.de website for breast cancer patients: User acceptance of a German internet portal offering information on the disease and treatment options, and a clinical trials matching service
por: Wallwiener, Markus, et al.
Publicado: (2010)

Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow
por: Volmer, Léa, et al.
Publicado: (2022)

Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers
por: Taran, Florin-Andrei, et al.
Publicado: (2018)

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients
por: Wallwiener, Markus, et al.
Publicado: (2015)

Tumor biomarker conversion between primary and metastatic breast cancer: mRNA assessment and its concordance with immunohistochemistry
por: Stefanovic, Stefan, et al.
Publicado: (2017)

Circulating and Disseminated Tumor Cells in Breast Carcinoma: Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
por: Fehm, Tanja, et al.
Publicado: (2009)

Update Breast Cancer 2019 Part 4 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer
por: Schütz, Florian, et al.
Publicado: (2019)

Update Breast Cancer 2017 – Implementation of Novel Therapies
por: Lux, Michael P., et al.
Publicado: (2017)

Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention
por: Schneeweiss, Andreas, et al.
Publicado: (2018)

Electronic-Based Patient-Reported Outcomes: Willingness, Needs, and Barriers in Adjuvant and Metastatic Breast Cancer Patients
por: Hartkopf, Andreas D, et al.
Publicado: (2017)

Update Breast Cancer 2019 Part 5 – Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2019)

Translational Highlights in Breast and Ovarian Cancer 2019 – Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy
por: Hartkopf, Andreas D., et al.
Publicado: (2019)

Update Breast Cancer 2019 Part 3 – Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Circulating and Disseminated Tumour Cells in Breast Carcinoma: Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Early dissemination seeds metastasis in breast cancer
por: Hosseini, Hedayatollah, et al.
Publicado: (2016)

Circulating tumour cells in breast cancer
por: Krawczyk, Natalia, et al.
Publicado: (2013)

Electrochemotherapy – Supplementary Treatment for Loco-regional Metastasized Breast Carcinoma Administered to Concomitant Systemic Therapy
por: Grischke, Eva-Maria, et al.
Publicado: (2017)

Expression of stem cell and epithelial-mesenchymal transition markers in primary breast cancer patients with circulating tumor cells
por: Kasimir-Bauer, Sabine, et al.
Publicado: (2012)

Reliability of an e-PRO Tool of EORTC QLQ-C30 for Measurement of Health-Related Quality of Life in Patients With Breast Cancer: Prospective Randomized Trial
por: Wallwiener, Markus, et al.
Publicado: (2017)

Sequencing for an interdisciplinary molecular tumor board in patients with advanced breast cancer: experiences from a case series
por: Walter, Christina, et al.
Publicado: (2020)

An Electronic Patient-Reported Outcome Tool for the FACT-B (Functional Assessment of Cancer Therapy-Breast) Questionnaire for Measuring the Health-Related Quality of Life in Patients With Breast Cancer: Reliability Study
por: Matthies, Lina Maria, et al.
Publicado: (2019)

Molecular Subtype Conversion between Primary and Metastatic Breast Cancer Corresponding to the Dynamics of Apoptotic and Intact Circulating Tumor Cells
por: Stefanovic, Stefan, et al.
Publicado: (2019)

Multidisciplinary breast centres in Germany: a review and update of quality assurance through benchmarking and certification
por: Wallwiener, Markus, et al.
Publicado: (2012)

Circulating miR-200 family as predictive markers during systemic therapy of metastatic breast cancer
por: Fischer, Chiara, et al.
Publicado: (2022)

Circulating miR-200 Family and CTCs in Metastatic Breast Cancer before, during, and after a New Line of Systemic Treatment
por: Fischer, Chiara, et al.
Publicado: (2022)

Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
por: Lux, Michael P., et al.
Publicado: (2018)

ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients
por: Fehm, Tanja, et al.
Publicado: (2008)

Recurrence Score(®) Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial
por: Dannehl, Dominik, et al.
Publicado: (2022)

Hospital versus individual surgeon’s performance in laparoscopic hysterectomy
por: Driessen, Sara R. C., et al.
Publicado: (2016)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay
por: Fehm, Tanja, et al.
Publicado: (2012)

Measurement of tumour size with mammography, sonography and magnetic resonance imaging as compared to histological tumour size in primary breast cancer
por: Gruber, Ines V, et al.
Publicado: (2013)

Microfluidic Isolation of Disseminated Tumor Cells from the Bone Marrow of Breast Cancer Patients
por: Volmer, Léa L., et al.
Publicado: (2023)

Estrogen, progesterone, and human epidermal growth factor receptor 2 discordance between primary and metastatic breast cancer
por: Walter, Vincent, et al.
Publicado: (2020)

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
por: Michel, Laura L., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_t4958tciul4390lrgncodtnuun